IBRX / ImmunityBio stock loses more than half its value after disclosing FDA can't approve the BLA for its cancer treatment in its present form

ImmunityBio, Inc.'s drug Anktiva received a Complete Response Letter, or CRL, from the FDA, delaying its approval for the treatment of NMIBC. The CRL more_horizontal

The clinical-stage biotech's lead therapy is in trials to treat bladder cancer. The sale of company stock helped raise $470 million. more_horizontal

After I spent many years following Wall Street, there are a few characteristics about the “big money”  that stand out for me. One of these traits more_horizontal

ImmunityBio is a clinical-stage biotech company. The company's lead therapy candidate is Anktiva. more_horizontal

The FDA rejected the Anktiva marketing application last month. Since the troubles lie with an outside organization, the company has no control over th more_horizontal

Being an extremely volatile stock, ImmunityBio, Inc. is not for all investors. Nevertheless, there are tremendous opportunities in ImmunityBio stock f more_horizontal

FDA rejects ImmunityBio's (IBRX) filing seeking approval of Anktiva (N-803) as a combo-therapy in bladder cancer indication, citing deficiencies in an more_horizontal

ImmunityBio stock dropped over 50% after the FDA issued a CRL for Anktiva, their lead product for treating BCG-unresponsive non-muscle invasive bladde more_horizontal